 Home > Chemicals Industry > China Chemical > APIs become a new blue ocean, and related companies are favored

APIs become a new blue ocean, and related companies are favored

 Last Update: 2022-03-10
 Source: Internet
 Author: User

Tags

chemical rat poison

supplement companies

pharmaceutical companies indiana

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

[ Chemical Machinery Equipment Network Market Analysis ] With the development of the economy, the acceleration of social aging and the deteriorating living environment, the frequent occurrence of various diseases has led to the increasing awareness of people's health care, and it has also begun to promote the continuous expansion of the pharmaceutical market.
In the context of the continuous expansion of the pharmaceutical market, the scale of domestic APIs has also been directly driven and has shown an upward trend year by year.

Chemical machinery and equipment network market analysis chemical machinery and equipment

At present, after years of development, my country has become a major producer of raw materials and a major exporter of raw materials.
At the same time, the development of more and more domestic raw material pharmaceutical companies is increasingly optimistic.

Recently, Zhejiang East Asia Pharmaceutical Co.
, Ltd.
officially listed on the Shanghai Stock Exchange, issuing 28.
4 million shares at an issue price of 31.
13 yuan and a total fund-raising of 880 million yuan.
On the same day, the closing price of East Asia Pharmaceuticals was 44.
83 yuan, an increase of 44.
01% from the issue price; based on the closing price, the market value of East Asia Pharmaceuticals was 5.
093 billion yuan.
On the 26th, East Asia Pharmaceuticals had a daily limit, with a market value of 5.
6 billion yuan.

　　It is understood that the owner's business of East Asia Pharmaceuticals is the research and development, production and sales of chemical raw materials and pharmaceutical intermediates.
Statistics show that the performance of East Asia Pharmaceuticals is showing a steady growth trend in recent years.
From 2017 to 2019, the revenue of East Asia Pharmaceuticals was 729 million yuan, 856 million yuan, and 988 million yuan, respectively.

　　Although, from January to September 2020, due to the impact of the epidemic, East Asia Pharmaceutical's revenue was 678 million yuan, a year-on-year decrease of 6.
49%; the net profit attributable to shareholders of the parent company was 108 million yuan, a year-on-year decrease of 17.
20%.
However, it believes that with the continuous recovery of the market, the overall business situation of Asia Pharmaceuticals is expected to be better in 2020.
In fact, judging from the sharp rise in the stock price of East Asia Pharmaceuticals on the day of its listing, its development is indeed favored under the favorable environment.

　　In fact, since this year, due to the impact of a special period, APIs have become the focus of market attention.
At present, with the closing of the three quarterly reports, API companies with outstanding performance, such as Huahai Pharmaceutical and Anglikang, are increasingly favored by the industry.

　　According to public information, on October 20, Huahai Pharmaceutical released its third quarterly report for 2020, 20Q1~3.
It realized operating income of 4.
87 billion yuan, net profit of 841 million yuan attributable to the parent, and net profit of 781 million yuan deducted from the parent.
The performance is in line with expectations.
In the context of a better environment and rapid growth in performance, Huahai Pharmaceutical expects that with the lifting of the FDA ban in the future, the revenue of existing products is expected to double.

　　On October 27, Anglikang also released the 2020 three quarterly report.
During the reporting period, the company achieved a net profit of 124 million yuan attributable to shareholders of listed companies, an increase of 37.
41% over the same period last year.
In addition, it also forecasted its full-year performance.
It is estimated that the net profit attributable to shareholders of listed companies in 2020 will increase by 65%-95% over the same period of the previous year.

　　In general, with the in-depth advancement of pharmaceutical policy reforms such as national consistency evaluation, related review, and volume procurement, as well as the tightening of domestic environmental protection policies and the improvement of drug quality standards, the strategic position of APIs is constantly being highlighted.
Related companies It is also becoming more and more popular.

　　However, it is worth noting that the current domestic API industry is still small, scattered, and chaotic, with low-price competition among enterprises, serious waste of resources, and overcapacity.
Therefore, under the dual pressure of industry integration and environmental protection upgrades, the API industry will experience a transitional period in the future.
While developing in a more specialized and large-scale direction, at least 70% of small and medium-sized enterprises will disappear in the future.
Companies with R&D, scale and product advantages "integrated API + preparation" are expected to have more opportunities.

　　Original title: APIs become a new blue ocean, and related companies are favored

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.